PARTNERSHIPS FOR NOVEL THERAPEUTIC, DIAGNOSTIC AND VECTOR CONTROL STRATEGIES IN INFECTIOUS DISEASES - ADDENDUM TO PAR-02-026 Release Date: January 25, 2002 NOTICE: NOT-AI-02-007 (also see PAR-02-026, NOT-AI-02-22, NOT-AI-02-013) National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/default.htm) Receipt Date: March 20, 2002, NEW June 20, 2002 The National Institute of Allergy and Infectious Diseases is adding additional language as well as an additional receipt date to PAR-02-026 at http://www.niaid.nih.gov/ncn/pa/PAR-02-026.html. An additional receipt date of June 20,2002 has been added. Under Research Objectives and Scope a 4th area will be added: #4. Development of Vaccines for Selected Agents of Bioterrorism: Responsive applications to scientific area "4." include those that propose to develop vaccines to prevent infection and/or disease from CDC Category A agents of bioterrorism (B. anthracis, Clostridium botulinum. Yersinia pestis, Variola major, Francisella tularensis and causative pathogens of viral hemorrhagic fevers). Proposed research may fall anywhere along a broad spectrum of activities from candidate identification and validation through preclinical development and early human testing (Phase I and II trials). Under Review Criteria #1 and #3 have been modified and replaced with the following: 1. Significance. Is this project likely to result in or significantly advance development of a novel vaccine, therapeutic or vector control agent/strategy or diagnostic technique that will add substantively to our ability to prevent diagnose, treat or control an infectious disease of public health importance? Is the industry commitment adequate to have an impact on the success of the proposed research objectives? If the aims of the application are achieved, are important biomedical agents or diagnostic technologies likely to result? What will be the effect of these studies on the concepts or methods that drive this field? 3. Innovation. Many aspects of vaccine drug, diagnostic and vector control method development are not inherently innovative. However, each project will be judged on whether, if successful in completing its aims, the project will add substantially to our ability to prevent, diagnose, treat or control an infectious disease that currently causes a public health burden and is not currently considered an attractive investment by the private sector (i.e., biotechnology, chemical or pharmaceutical industry). Complete information about the grant program, PAR-02-026 may be obtained at http://grants.nih.gov/grants/guide/pa-files/PAR-02-026.html. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic, research scope, and eligibility issues to: Ann M. Ginsberg, M.D., Ph.D. Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases Room 3133, MSC-7630 6700-B Rockledge Drive Bethesda, MD 20892-7630 Telephone: (301) 496-5305 FAX: (301) 496-8030 E-Mail: ag73i@nih.gov Direct inquiries regarding fiscal matters to: Ms. Jeanette Gorden Division of Extramural Activities National Institute of Allergy and Infectious Diseases Room 3222, MSC-7614 6700-B Rockledge Drive Bethesda, MD 20892-7614 Telephone: (301) 402-5065 Fax: (301) 480-3780 E-mail: jgorden@niaid.nih.gov
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |